Boston Scientific Receives FDA Approval for Innovative Deep Brain Stimulation Software

Boston Scientific, a leading medical technology company, has achieved a significant milestone with the recent FDA approval of its image-guided programming software for deep brain stimulation (DBS). The newly approved software, known as Vercise Neural Navigator 5 with StimView XT technology, promises to revolutionize the treatment of neurological conditions like Parkinson's disease and essential tremor.

Deep brain stimulation is a highly effective therapy for patients suffering from movement disorders. The Vercise Genus DBS system, developed by Boston Scientific, targets specific brain tissue using implantable pulse generators (IPGs) and brain leads. What sets this system apart is its conditional MRI usage approval received in 2021, making it more versatile and adaptable for patients' needs.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The system incorporates both Bluetooth-enabled rechargeable and non-rechargeable IPGs to power the Vercise Cartesia directional leads, providing a wide range of options to suit individual patient requirements.

The breakthrough software, co-created by Boston Scientific and Brainlab AG at their Marlborough, Massachusetts facility, promises to streamline the DBS programming process significantly. Clinicians will now receive concise, actionable data from the Vercise Genus equipment, allowing for more efficient and personalized patient treatment.

One of the software's standout features is its ability to display and stimulate each patient's brain structure in real time. This groundbreaking technology provides clinicians with a unique insight into the brain's responses during stimulation, enabling them to tailor treatment with unmatched precision.

According to Boston Scientific, the image-guided DBS systems featuring Vercise Neural Navigator 5 with StimView XT can cut programming time by a staggering 56%. This time-saving advantage translates to increased doctor-patient interaction, allowing clinicians to focus more on patient needs and overall care.

Dr. Mustafa Saad Siddiqui, a respected neurology and neurosurgery professor at Wake Forest School of Medicine and medical director of the Atrium Health Wake Forest Baptist DBS program, praised the newly approved software. He emphasized that it optimizes patient treatment benefits by offering clinicians a simpler patient data interface and advanced settings to deliver more personalized therapy.

Boston Scientific's Neuromodulation President, Jim Cassidy, expressed excitement over the potential impact of this software on patients' lives. He stated, "Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions."

The complexity and time-consuming nature of DBS therapy have been challenges for both clinicians and patients. However, with this innovative software, Boston Scientific aims to address these issues, empowering clinicians with a higher level of flexibility to effectively treat individual patients at different phases of their condition.

The FDA's approval of Vercise Neural Navigator 5 with StimView XT marks a significant step forward in the field of DBS therapy. It represents the company's commitment to advancing medical technology to enhance the lives of those affected by neurological disorders. As the software becomes available for clinical use, it has the potential to bring about a new era of personalized and efficient deep brain stimulation, offering hope to countless individuals seeking relief from debilitating movement disorders.